Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
Pfizer Inc. (NYSE: PFE) has declared a
Pfizer (NYSE: PFE) has announced an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™, to the Global Fund for low-and-middle-income countries. These treatment courses will be available for procurement in 132 eligible countries beginning in 2022, pending regulatory approval. The agreement is part of Pfizer's strategy for equitable access to COVID-19 treatments. Additionally, Pfizer has established tiered pricing for different income classifications and signed prior agreements with UNICEF and the Medicines Patent Pool to enhance global access.
Pfizer Inc. (NYSE: PFE) is hosting a conference call for investors on November 1, 2022, at 10 a.m. EDT to discuss its Third Quarter 2022 Performance Report. The call will provide insights into the company's financial results and future strategies. Interested participants can join via webcast or by dialing specific numbers for different regions. Details for accessing the Performance Report and registration can be found on Pfizer's investor website, with a transcript available within 24 hours post-call.
Pfizer announced positive results from its pivotal Phase 3 study (NCT04546425) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC), targeting invasive pneumococcal disease in infants. The vaccine showed a favorable safety profile and robust immune responses, meeting non-inferiority criteria for 19 of 20 serotypes after the third dose. Pfizer intends to file for regulatory approval in the EU in the upcoming months. This vaccine, if approved, would provide comprehensive protection against pneumococcal disease, marking a significant milestone in pediatric vaccination.
Pfizer announced positive results from the Phase 3 trial of its investigational pentavalent meningococcal vaccine, MenABCWY, demonstrating safety and immunogenicity non-inferior to existing licensed vaccines. The trial met all primary and secondary endpoints, providing broad serogroup coverage. Pfizer plans to submit a Biologics License Application to the FDA in Q4 2022, which, if approved, could simplify the vaccination schedule for approximately 52 million adolescents in the U.S. and improve meningococcal disease protection.
Pfizer Inc. (NYSE: PFE) will hold a conference call on September 21, 2022, at 4:30 p.m. EDT, focusing on oral GLP-1 data from the European Association for the Study of Diabetes 2022. Investors can join the webcast via Pfizer's investor site, and are encouraged to register in advance. Participants can also listen by calling 800-456-4352 (U.S. and Canada) or 785-424-1086 (international), with passcode “70409”. A transcript and replay will be available for 90 days on the investor site.
Pfizer Inc. (NYSE: PFE) has initiated a pivotal Phase 3 clinical trial for its mRNA-based influenza vaccine, enrolling approximately 25,000 healthy adults in the U.S. This study aims to evaluate the vaccine's efficacy, safety, and immunogenicity. With influenza annually causing up to 710,000 hospitalizations and 52,000 deaths in the U.S., the need for improved vaccines is critical. mRNA technology may allow better strain matches and more rapid production, potentially enhancing vaccine effectiveness.
Pfizer (NYSE: PFE) has expanded its collaboration with Strata Oncology for the Strata PATH trial, which will now include treatment for new micrometastatic patient cohorts. Pfizer will provide several FDA-approved cancer therapies, including Braftovi® and Lorbrena®, for patients with early-stage cancer showing micrometastatic disease. The trial aims to evaluate the safety and efficacy of these therapies on a broader patient population. This initiative underscores the potential of precision oncology in advancing cancer treatment.
Pfizer and BioNTech have received a conditional marketing authorization recommendation from the EMA's CHMP for their bivalent Omicron BA.4/BA.5 COVID-19 vaccine for individuals 12 years and older. The vaccine combines components targeting both the original SARS-CoV-2 and Omicron subvariants, designed to elicit a strong immune response. If approved by the European Commission, distribution will commence immediately to support EU vaccination efforts this fall. Previous data showed a superior immune response against Omicron subvariants compared to the existing vaccine.
Pfizer Inc. (NYSE: PFE) announced that the FDA accepted the New Drug Application (NDA) for ritlecitinib for treating alopecia areata in adults and adolescents. The FDA decision is expected in Q2 2023, while the EMA's Marketing Authorization Application (MAA) decision is anticipated in Q4 2023. Ritlecitinib is a new oral treatment aimed at regrowing hair, showing statistically significant results in clinical trials. Alopecia areata affects approximately 6.8 million people in the U.S. and around 147 million globally.
